Protocol Ledger

NCT05915702 · Phase III · COMPLETED

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Interventional Phase III clinical trial protocol NCT05915702 sponsored by Bayer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-24 Enrollment: 321 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05915702
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)321 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05915702
Protocol FieldVerified Registry Value
NCT IdentifierNCT05915702
Consolidated Lead SponsorBayer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment321 participants (ACTUAL)
Registered Start Date2023-07-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI